US FDA staff raise no major concerns about Eli Lilly Alzheimer's drug
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Eli Lilly (LLY) PT Raised to $957 at Jefferies
June 6, 2024 4:27 PM EDTJefferies analyst Akash Tewari raised the price target on Eli Lilly (NYSE: LLY) to $957.00 (from $925.00) while maintaining a Buy rating.
The analyst comments "Dona's Ad Com documents look fine we note 1) FDA didn't agree w/ LLY on changing primary endpoint but believes data supports... More
